{"slug":"retatrutide-skin","verification":{"valid":true,"entries":2,"head":"59fe520dff9c10c84a6711b67bcde8ba1925d399edfa552e39e61001f56feea1"},"energy":{"passes":2,"tokens_in":14273,"tokens_out":3558,"tokens_total":17831,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"59fe520dff9c10c84a6711b67bcde8ba1925d399edfa552e39e61001f56feea1"},"provenance":[{"ts":"2026-06-30T00:51:17.071Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Skin\nSlug: retatrutide-skin\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant","response":"{\n  \"slug\": \"retatrutide-skin\",\n  \"title\": \"Retatrutide and Skin: Evidence-Graded Look at Metabolic Load Reduction\",\n  \"body\": \"## What's breaking down\\n\\nSkin health involves multiple layers that can degenerate when metabolic factors like excess body weight are present. Excess adipose tissue is linked to chronic low-grade inflammation and mechanical stretching of skin. Rapid changes in body composition can outpace the skin's ability to adapt its elasticity and structure. No direct skin degeneration profile is defined in the query, so layers are inferred from retatrutide's studied effects on body weight.\\n\\n## Why Retatrutide might help you\\n\\n1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nThe same weight-loss pathway may indirectly relate to skin by altering overall metabolic load, though trial data show skin sensations as a reported event rather than improvement.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Retatrutide** → metabolic load / body weight\\n\\n## What the evidence actually shows\\n\\nHuman trials (Phase 2 and Phase 3) report cutaneous hyperesthesia or dysesthesia (altered skin sensations such as tingling or sensitivity) in roughly 7% of participants on retatrutide versus 1% on placebo in Phase 2; rates reached 5-12.5% at higher doses in Phase 3 (human tier). These events were generally mild to moderate and did not lead to discontinuation in most cases (human tier). No human trials demonstrate direct skin repair, regeneration, or ela","tokens_in":14273,"tokens_out":3558,"cost":0,"prev":"genesis","hash":"9d3a3e619586a1982bf67bb6bb71ab06a5c8982ca768ad4595f837a32ff57db9"},{"ts":"2026-07-17T02:41:21.185Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-skin","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9d3a3e619586a1982bf67bb6bb71ab06a5c8982ca768ad4595f837a32ff57db9","hash":"59fe520dff9c10c84a6711b67bcde8ba1925d399edfa552e39e61001f56feea1"}]}